JP2000508673A5 - - Google Patents

Download PDF

Info

Publication number
JP2000508673A5
JP2000508673A5 JP1997537711A JP53771197A JP2000508673A5 JP 2000508673 A5 JP2000508673 A5 JP 2000508673A5 JP 1997537711 A JP1997537711 A JP 1997537711A JP 53771197 A JP53771197 A JP 53771197A JP 2000508673 A5 JP2000508673 A5 JP 2000508673A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997537711A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000508673A (ja
JP5037746B2 (ja
Filing date
Publication date
Priority claimed from DE19615812A external-priority patent/DE19615812A1/de
Application filed filed Critical
Publication of JP2000508673A publication Critical patent/JP2000508673A/ja
Publication of JP2000508673A5 publication Critical patent/JP2000508673A5/ja
Application granted granted Critical
Publication of JP5037746B2 publication Critical patent/JP5037746B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP53771197A 1996-04-20 1997-04-21 イバンドロネートを含む経口薬理製剤 Expired - Lifetime JP5037746B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19615812.5 1996-04-20
DE19615812A DE19615812A1 (de) 1996-04-20 1996-04-20 Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
PCT/EP1997/001940 WO1997039755A1 (de) 1996-04-20 1997-04-21 Orale pharmazeutische zubereitung enthaltend ibandronat

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008178294A Division JP5557989B2 (ja) 1996-04-20 2008-07-08 イバンドロネートを含む経口薬理製剤

Publications (3)

Publication Number Publication Date
JP2000508673A JP2000508673A (ja) 2000-07-11
JP2000508673A5 true JP2000508673A5 (enExample) 2005-01-13
JP5037746B2 JP5037746B2 (ja) 2012-10-03

Family

ID=7791961

Family Applications (2)

Application Number Title Priority Date Filing Date
JP53771197A Expired - Lifetime JP5037746B2 (ja) 1996-04-20 1997-04-21 イバンドロネートを含む経口薬理製剤
JP2008178294A Expired - Lifetime JP5557989B2 (ja) 1996-04-20 2008-07-08 イバンドロネートを含む経口薬理製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008178294A Expired - Lifetime JP5557989B2 (ja) 1996-04-20 2008-07-08 イバンドロネートを含む経口薬理製剤

Country Status (26)

Country Link
US (2) US6143326A (enExample)
EP (2) EP1658852B1 (enExample)
JP (2) JP5037746B2 (enExample)
CN (1) CN101152160A (enExample)
AR (2) AR006652A1 (enExample)
AT (1) ATE404207T1 (enExample)
AU (1) AU722516B2 (enExample)
BR (1) BR9708785A (enExample)
CA (1) CA2251886C (enExample)
CO (1) CO4820394A1 (enExample)
CZ (1) CZ297341B6 (enExample)
DE (2) DE19615812A1 (enExample)
DK (1) DK0936913T4 (enExample)
ES (1) ES2313735T5 (enExample)
HU (1) HU228389B1 (enExample)
IL (2) IL163930A0 (enExample)
NO (1) NO319162B1 (enExample)
NZ (1) NZ332314A (enExample)
PA (1) PA8427301A1 (enExample)
PL (2) PL191910B1 (enExample)
PT (1) PT936913E (enExample)
RU (1) RU2193881C2 (enExample)
SI (1) SI0936913T2 (enExample)
TR (1) TR199802108T2 (enExample)
WO (1) WO1997039755A1 (enExample)
ZA (1) ZA973331B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
RU2193880C2 (ru) * 1997-06-11 2002-12-10 Дзе Проктер Энд Гэмбл Компани Покрытая пленкой таблетка улучшенной безопасности для верхних отделов желудочно-кишечного тракта
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
AR024462A1 (es) * 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
AU2001271055B2 (en) * 2000-07-17 2005-07-07 Astellas Pharma Inc. Pharmaceutical composition improved in peroral absorbability
JP2002332235A (ja) * 2001-02-01 2002-11-22 Riderway Corp 骨疾患治療用液体医薬組成物
AR034199A1 (es) * 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
BR0209360A (pt) * 2001-05-02 2004-06-08 Novartis Ag Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
BR0206441A (pt) * 2001-12-19 2003-12-30 Astrazeneca Ab Composição de revestimento de pelìcula, revestimento de pelìcula cobrindo um núcleo farmacêutico, formulação farmacêutica de liberação modificada, e, processos para preparar uma composição de revestimento de pelìcula, um revestimento de pelìcula e uma formulação
NZ532994A (en) * 2001-12-21 2008-05-30 Procter & Gamble Method for the treatment of bone disorders using a bisphosphonate regimen, risedronate in particular
MXPA04008164A (es) 2002-02-21 2005-05-17 Biovail Lab Inc Formas de dosificacion de liberacion controlada.
CA2481142C (en) * 2002-05-10 2012-11-13 F.Hoffmann-La Roche Ag Bisphosphonic acids for the treatment and prevention of osteoporosis
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
NZ555514A (en) * 2002-12-20 2008-12-24 Hoffmann La Roche High dose ibandronate formulation
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
RU2262923C2 (ru) * 2003-12-25 2005-10-27 Государственное образовательное учреждение высшего профессионального образования Курский государственный медицинский университет Министерства здравоохранения Российской Федерации Иммобилизованная форма доксорубицина
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
EP2001486A4 (en) * 2006-03-17 2010-12-29 Univ Illinois BIPHOSPHONATE COMPOUNDS AND CORRESPONDING METHODS
CN101495101B (zh) * 2006-07-25 2012-02-29 兴和株式会社 糖衣制剂及其制造方法
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
WO2009075601A1 (fr) * 2007-12-12 2009-06-18 Alexander Valerievich Melnik Moyen d'indication d'une éventuelle prédisposition de chats à une maladie (variantes) et procédé de détermination de troubles de la santé chez les chats
EP2210596A1 (en) 2009-01-22 2010-07-28 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
CN103079596B (zh) * 2010-08-31 2015-08-19 东丽株式会社 药物固体制剂用的包衣剂、药物用膜制剂以及包覆药物固体制剂
CA2839494C (en) * 2011-06-17 2018-11-06 Evonik Roehm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
RU2485957C1 (ru) * 2012-03-16 2013-06-27 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия последипломного образования" Министерства здравоохранения Российской Федерации (ГБОУ ДПО РМАПО Минздрава России) Средство для лечения низкообменного варианта заболевания скелета у больных с хронической почечной недостаточностью

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE965825C (de) 1949-10-30 1957-06-19 Walter Kloepfer Dipl Ing Dr In Zur Antennenebene senkrecht polarisierter Strahler
US4820698A (en) * 1985-11-04 1989-04-11 The Procter & Gamble Company Antimicrobial agents and process for their manufacture
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5098717A (en) * 1987-12-09 1992-03-24 Thames Pharmacal Co., Inc. Method of treatment for pruritus
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
TW237386B (enExample) * 1992-04-15 1995-01-01 Ciba Geigy
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
RU2134103C1 (ru) * 1993-05-15 1999-08-10 Берингер Маннхайм ГмбХ Таблетка с улучшенной биодоступностью биологически активного вещества и вещество, повышающее биодоступность
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
US5803321A (en) * 1996-11-12 1998-09-08 Randy Hangers, Lll Hanger with ganging element
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2000501324A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000501825A5 (enExample)
JP2000500874A5 (enExample)
JP2000502425A5 (enExample)
JP2000502485A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2000501744A5 (enExample)
JP2000501229A5 (enExample)
JP2000502316A5 (enExample)
JP2000500857A5 (enExample)
JP2000502714A5 (enExample)
JP2000501569A5 (enExample)
JP2000500184A5 (enExample)
JP2000500318A5 (enExample)